Witjes - Figure 35
Cochrane Review
FIG. 35: Some years ago a review of data from trials carried out with intravesical gemcitabine (Figure) showed that gemcitabine is less effective than BCG in high-risk patients, but in BCG refractory patients it is superior to BCG.[18] However, that evidence was limited by the differences in clinical settings among the studies reviewed. So although gemcitabine may be promising,[19] more studies are needed to support its use.
References
Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review. BJU Int. 2012;109:496−505 https:///doi.org/10.1111/j.1464-410X.2011.10880.x
Gontero P, Oderda M, Mehnert A, et al. The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190:857−62 http://dx.doi.org/10.1016/j.juro.2013.03.097
